Department of Integrative Physiology, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia.
Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia-Okanagan, Kelowna, BC, Canada.
Adv Ther. 2023 Aug;40(8):3495-3511. doi: 10.1007/s12325-023-02560-8. Epub 2023 Jun 8.
Studies reveal that cannabidiol may acutely reduce blood pressure and arterial stiffness in normotensive humans; however, it remains unknown if this holds true in patients with untreated hypertension. We aimed to extend these findings to examine the influence of the administration of cannabidiol on 24-h ambulatory blood pressure and arterial stiffness in hypertensive individuals.
Sixteen volunteers (eight females) with untreated hypertension (elevated blood pressure, stage 1, stage 2) were given oral cannabidiol (150 mg every 8 h) or placebo for 24 h in a randomised, placebo-controlled, double-blind, cross-over study. Measures of 24-h ambulatory blood pressure and electrocardiogram (ECG) monitoring and estimates of arterial stiffness and heart rate variability were obtained. Physical activity and sleep were also recorded.
Although physical activity, sleep patterns and heart rate variability were comparable between groups, arterial stiffness (~ 0.7 m/s), systolic blood pressure (~ 5 mmHg), and mean arterial pressure (~ 3 mmHg) were all significantly (P < 0.05) lower over 24 h on cannabidiol when compared to the placebo. These reductions were generally larger during sleep. Oral cannabidiol was safe and well tolerated with no development of new sustained arrhythmias.
Our findings indicate that acute dosing of cannabidiol over 24 h can lower blood pressure and arterial stiffness in individuals with untreated hypertension. The clinical implications and safety of longer-term cannabidiol usage in treated and untreated hypertension remains to be established.
研究表明,大麻二酚可能会使血压正常的人血压和动脉僵硬度急性下降;然而,在未经治疗的高血压患者中是否如此还不得而知。我们旨在扩展这些发现,以检查大麻二酚给药对高血压个体 24 小时动态血压和动脉僵硬度的影响。
16 名未经治疗的高血压志愿者(8 名女性)接受了口服大麻二酚(每 8 小时 150mg)或安慰剂治疗 24 小时,采用随机、安慰剂对照、双盲、交叉研究。测量 24 小时动态血压和心电图(ECG)监测以及动脉僵硬度和心率变异性的估计值,并记录体力活动和睡眠情况。
尽管两组之间的体力活动、睡眠模式和心率变异性相似,但与安慰剂相比,大麻二酚在 24 小时内使动脉僵硬度(0.7m/s)、收缩压(5mmHg)和平均动脉压(~3mmHg)均显著降低(P<0.05)。这些降低在睡眠期间通常更大。口服大麻二酚安全且耐受良好,没有新的持续性心律失常发生。
我们的发现表明,在未经治疗的高血压患者中,24 小时内急性给予大麻二酚可降低血压和动脉僵硬度。在治疗和未治疗的高血压中,长期使用大麻二酚的临床意义和安全性仍有待确定。